SESN Key Statistics, Chart & Performance
The current stock price of SESN is 0.6288 USD. In the past month the price increased by 8.32%. In the past year, price increased by 0.5%.
SESN Latest News, Press Relases and Analysis
SESN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About SESN
Company Profile
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Company Info
SESEN BIO INC
245 1st St Ste 1800
Cambridge MASSACHUSETTS 02142 US
CEO: Thomas R. Cannell
Employees: 35
Phone: 16174448550.0
SESEN BIO INC / SESN FAQ
Can you describe the business of SESEN BIO INC?
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Can you provide the latest stock price for SESEN BIO INC?
The current stock price of SESN is 0.6288 USD. The price increased by 7.29% in the last trading session.
Does SESEN BIO INC pay dividends?
SESN does not pay a dividend.
How is the ChartMill rating for SESEN BIO INC?
SESN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for SESN stock?
SESEN BIO INC (SESN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).
Is SESEN BIO INC (SESN) expected to grow?
The Revenue of SESEN BIO INC (SESN) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does SESEN BIO INC have?
SESEN BIO INC (SESN) currently has 35 employees.
SESN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to SESN. When comparing the yearly performance of all stocks, SESN is one of the better performing stocks in the market, outperforming 90% of all stocks.
SESN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SESN. While SESN seems to be doing ok healthwise, there are quite some concerns on its profitability.
SESN Financial Highlights
Over the last trailing twelve months SESN reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS decreased by -364% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SESN Forecast & Estimates
6 analysts have analysed SESN and the average price target is 12.24 USD. This implies a price increase of 1846.56% is expected in the next year compared to the current price of 0.6288.
For the next year, analysts expect an EPS growth of -308% and a revenue growth -100% for SESN